Aktie A128940 HANMI PHARM. CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Hanmi Pharm. Co., Ltd.

Aktien

A128940

KR7128940004

A128940

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
316 500 KRW +0,80 % Intraday Chart für Hanmi Pharm. Co., Ltd. -2,31 % -10,21 %
01.05. Hanmi Pharm Q1 Gewinn steigt um 27,5%, Umsatz um 11,8% MT
19.03. Hanmi Pharm. Co. Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Invion Partners with Hanlim Pharma for Glioblastoma Treatment
Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8%
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.
Aptose Biosciences Inc. announced that it expects to receive $4 million in funding from Hanmi Pharm. Co., Ltd.
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Allergic Rhinitis Pipeline, Clinical Trials, Key Companies
Hanmi Pharm's Q3 Income Surges 94%
Allergic Rhinitis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib First-in-Class Candidate for the Treatment of Intermediate Dry AMD
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aptose Biosciences Inc. announced that it expects to receive $6.999998 million in funding from Hanmi Pharm. Co., Ltd.
Hanmi Pharm's Net Income Declines in Q2
Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Hanmi Pharm's Net Income Climbs in Q1
Assertio Holdings, Inc. (NasdaqCM : ASRT) entered into a definitive agreement to acquire Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI) for approximately $250 million.
Hanmi Pharm. Co., Ltd.'s Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirms Non-inferiority Efficacy and Safety Compared to Monotherapy in The Lancet' & 'European Heart Journal
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type
Hanmi Pharm's Net Income Plunges 23.7% in Q4
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A128940 Aktie
  4. Nachrichten Hanmi Pharm. Co., Ltd.
  5. Andere Sprachen